No Data
Shanghai Shyndec Pharmaceutical (600420.SH): Cefoperazone acetate tablets have obtained a Pharmaceutical registration certificate.
On December 11, Guolonghui reported that Shanghai Shyndec Pharmaceutical (600420.SH) announced that its holding subsidiary, China National Pharmaceutical Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd., received the drug registration certificate for Cefoperazone Ester Tablets approved and issued by the National Medical Products Administration. Cefoperazone Ester Tablets are oral third-generation cephalosporin antibiotics, effective against both Gram-positive and Gram-negative bacteria. They are used to treat upper respiratory infections, lower respiratory infections, uncomplicated urinary tract infections, uncomplicated skin and soft tissue infections, acute uncomplicated gonococcal urethritis and cervicitis, and perianal infections caused by Neisseria gonorrhoeae, among others.
Shyndec Pharma Unit's Codeine Phosphate Included in China's Listing of Chemical Raw Materials
Shanghai Shyndec Pharmaceutical (600420.SH) subsidiary's phosphoric acid codeine active pharmaceutical ingredient obtained approval for marketing application.
Shanghai shyndec pharmaceutical (600420.SH) announced that recently, its wholly-owned subsidiary China National Pharmaceutical Group Industrial Co., Ltd. (...)
Shanghai Shyndec Pharmaceutical's (SHSE:600420) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection
Shanghai Shyndec Pharmaceutical CFO Resigns
